B 244

Drug Profile

B 244

Alternative Names: B244; D-23

Latest Information Update: 18 Apr 2017

Price : $50

At a glance

  • Originator AOBiome
  • Class Antiacnes; Antibacterials; Bacteria
  • Mechanism of Action Bacteria replacements; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Acne vulgaris
  • Phase II Atopic dermatitis; Hypertension; Rosacea
  • Phase I Allergic rhinitis
  • Preclinical Skin disorders; Staphylococcal infections; Wounds

Most Recent Events

  • 13 Apr 2017 AOBiome completes enrolment in a phase II clinical trial in Hypertension in USA
  • 01 Nov 2016 Phase-II clinical trials in Hypertension in USA (Topical) (9209036; NCT02998840)
  • 19 Sep 2016 Phase-I clinical trials in Allergic rhinitis in USA (unspecified route) prior to September 2016 (AOBiome Therapeutic Pipeline, September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top